Affordable HIV Prevention Shot Receives U.S. Approval
On Monday, November 2, 2026, the US Food and Drug Administration (FDA) granted tentative approval for a cost-effective generic version of lenacapavir, a revolutionary HIV prevention injection administered twice a year.Produced by Dr. Reddy's Laboratories, an Indian company, this generic medication will be priced at $40 per person annually in 120 low- and middle-income nations. This is a stark contrast to the brand-name alternative, Yeztugo, manufactured by Gilead Sciences, which has a staggering US list price of $28,218 per year.This approval marks a significant triumph for advocates of global health, although there are still critical access gaps that need to be addressed. Lenacapavir functions as a capsid inhibitor, targeting the protein shell that safeguards the virus's genetic material, effectively preventing its replication.Clinical trials have demonstrated its effectiveness, showing over 99.9% efficacy in preventing HIV transmission.Because Gilead retains the active patent for this drug in the United States, the generic version cannot be marketed within the US. The FDA has granted "tentative approval" as part of a program aimed at ensuring the quality of drugs supplied globally by the US government, including through initiatives like PEPFAR.The rollout is anticipated to commence within weeks in select early-adopter regions, although it may take longer in countries that require localized regulatory assessments.Nonetheless, the program has faced substantial criticism regarding geographic limitations and access challenges. Gilead’s voluntary licensing agreements encompass 120 low- and lower-middle-income countries (LLMICs). Through this agreement, licensees are permitted to manufacture generic lenacapavir for an estimated cost of $40 per person annually.Primary Focus: Nations with high incidence rates and limited resources, primarily in Sub-Saharan Africa and parts of South/Southeast Asia.Priority Nations: 18 specific countries—including South Africa, Kenya, Uganda, Zambia, Zimbabwe, Tanzania, Botswana, Nigeria, and the Philippines—have been identified for expedited regulatory review and initial distribution.The voluntary license clearly omits several upper-middle-income countries (UMICs) and high-income nations, compelling them to negotiate directly with Gilead at much higher branded prices.Most of Latin America is left out of the generic license. Notably, countries such as Brazil, Mexico, Argentina, Colombia, and Peru are excluded, even though they participated in the crucial clinical trials (PURPOSE 2) for the drug.Nevertheless, global health organizations like Médecins Sans Frontières (MSF) and Civil Society Campaigns have voiced significant concerns regarding Gilead's rollout strategy.Although the $40 annual price makes the drug very accessible, local health systems need to adapt. This is essential because using lenacapavir while having an undiagnosed infection can result in drug-resistant strains of HIV; therefore, patients must undergo rapid HIV testing before each semi-annual injection.Global health agencies are now shifting their focus to assist local clinics with testing logistics and rollout initiatives.